Cargando…

Soluble epidermal growth factor receptor (sEGFR) and carcinoembryonic antigen (CEA) concentration in patients with non-small cell lung cancer: correlation with survival after erlotinib and gefitinib treatment

BACKGROUND: In patients with non-small cell lung cancer (NSCLC), a higher response rate can be achieved with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) when selection for therapy is guided by mutation analysis or gene amplification. However, both tests are complex and re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kappers, I, Vollebergh, M A, van Tinteren, H, Korse, C M, Nieuwenhuis, L L, Bonfrer, J M G, Klomp, H M, van Zandwijk, N, van den Heuvel, M M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cancer Intelligence 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234018/ https://www.ncbi.nlm.nih.gov/pubmed/22276032 http://dx.doi.org/10.3332/ecancer.2010.178

Ejemplares similares

Soluble Epidermal Growth Factor Receptors (sEGFRs) in Cancer: Biological Aspects and Clinical Relevance
por: Maramotti, Sally, et al.
Publicado: (2016)

Carcinoembryonic antigen (CEA) "fingerprints".
por: Rule, A. H., et al.
Publicado: (1973)

First British standard for carcinoembryonic antigen (CEA).
por: Laurence, D. J., et al.
Publicado: (1975)

Epitopes of carcinoembryonic antigen (CEA) defined by monoclonal antibodies.
por: Price, M. R.
Publicado: (1988)

A monkey antigen crossreacting with carcinoembryonic antigen, CEA.
por: Engvall, E., et al.
Publicado: (1976)

Immunochemical studies of carcinoembryonic antigen (CEA) variants.
por: Ichiki, A. T., et al.
Publicado: (1976)

Predicting Tumor Responses to Gefitinib and Erlotinib
Publicado: (2005)

Tolerability of gefitinib in patients receiving treatment in everyday clinical practice
por: Zandwijk, N van
Publicado: (2003)

Correction: Predicting Tumor Responses to Gefitinib and Erlotinib
Publicado: (2012)

Localisation of monoclonal antibodies reacting with different epitopes on carcinoembryonic antigen (CEA)--implications for targeted therapy.
por: Boxer, G. M., et al.
Publicado: (1994)

Carcinoembryonic antigen (CEA) plasma levels in Michigan and Wisconsin dairy farmers.
por: Anderson, H A, et al.
Publicado: (1978)

Immunological Study of Carcinoembryonic Antigen (CEA) and a Related Glycoprotein
por: Darcy, D. A., et al.
Publicado: (1973)

Successful erlotinib rechallenge after both gefitinib- and erlotinib-induced interstitial lung diseases
por: Arakawa, Nobuhito, et al.
Publicado: (2013)

Prognostic and Predictive Value of Carcinoembryonic Antigen and Cytokeratin-19 Fragments Levels in Advanced Non-Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib
por: Jung, Minkyu, et al.
Publicado: (2012)

Biological therapy: approaches in colorectal cancer. Strategies to enhance carcinoembryonic antigen (CEA) as an immunogenic target.
por: Zbar, A. P., et al.
Publicado: (1998)

Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy
por: Li, Yang-Ling, et al.
Publicado: (2018)

Factors influencing variability of localisation of antibodies to carcinoembryonic antigen (CEA) in patients with colorectal carcinoma--implications for radioimmunotherapy.
por: Boxer, G. M., et al.
Publicado: (1992)

Urinary carcinoembryonic antigen (CEA)-like molecules and urothelial malignancy: a clinical appraisal.
por: Coombers, G. B., et al.
Publicado: (1975)

Immunological comparison of carcinoembryonic antigen (CEA) extracted from tumours of various organs: their use in radioimmunological CEA determinations.
por: Lamerz, R., et al.
Publicado: (1983)

Carcinoembryonic antigen (CEA) expression and heterogeneity in primary and autologous metastatic gastric tumours demonstrated by a monoclonal antibody.
por: Hockey, M. S., et al.
Publicado: (1984)

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
por: Pao, William, et al.
Publicado: (2005)

Efficacy of gefitinib or erlotinib in patients with squamous cell lung cancer
por: Song, Zhengbo, et al.
Publicado: (2013)

Case of Proteinuria, Worsening Hypertension, and Glomerular Endotheliosis With Erlotinib and Gefitinib
por: Latcha, Sheron, et al.
Publicado: (2018)

Proceedings: Measurement of carcinoembryonic antigen (CEA) in normal subjects and in various neoplastic and non-neoplastic disorders.
por: Franchimont, P., et al.
Publicado: (1974)

Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2-mediated resistance to gefitinib and erlotinib
por: Lemos, C, et al.
Publicado: (2009)

Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study
por: Emery, Ivette F, et al.
Publicado: (2009)

A Comprehensive Phylogenetic and Structural Analysis of the Carcinoembryonic Antigen (CEA) Gene Family
por: Pavlopoulou, Athanasia, et al.
Publicado: (2014)

Carcinoembryonic antigen (CEA) level, CEA ratio, and treatment outcome of rectal cancer patients receiving pre-operative chemoradiation and surgery
por: Yang, Kai-Lin, et al.
Publicado: (2013)

Carcinoembryonic Antigen (CEA)-Specific 4-1BB-Costimulation Induced by CEA-Targeted 4-1BB-Agonistic Trimerbodies
por: Mikkelsen, Kasper, et al.
Publicado: (2019)

Postoperative carcinoembryonic antigen (CEA) levels predict outcomes after resection of colorectal cancer in patients with normal preoperative CEA levels
por: Zhang, Chiming, et al.
Publicado: (2020)

Successful Erlotinib Treatment for a Patient with Gefitinib-Related Hepatotoxicity and Lung Adenocarcinoma Refractory to Intermittently Administered Gefitinib
por: Nagano, Tatsuya, et al.
Publicado: (2011)

Comparison of CA 19-9 and carcinoembryonic antigen (CEA) levels in the serum of patients with colorectal diseases.
por: Kuusela, P., et al.
Publicado: (1984)

Expression of carcinoembryonic antigen (CEA) and nonspecific crossreacting antigen (NCA) in gastrointestinal cancer; the correlation with degree of differentiation.
por: Kodera, Y., et al.
Publicado: (1993)

Gefitinib and Erlotinib Lead to Phosphorylation of Eukaryotic Initiation Factor 2 Alpha Independent of Epidermal Growth Factor Receptor in A549 Cells
por: Koyama, Satoshi, et al.
Publicado: (2015)

The effect of combined treatment with sodium phenylbutyrate and cisplatin, erlotinib, or gefitinib on resistant NSCLC cells
por: Al-Keilani, Maha S, et al.
Publicado: (2018)

Phylogenetic discordance of human and canine carcinoembryonic antigen (CEA, CEACAM) families, but striking identity of the CEA receptors will impact comparative oncology studies.
por: Weichselbaumer, Marlene, et al.
Publicado: (2011)

Hookah smoking and cancer: carcinoembryonic antigen (CEA) levels in exclusive/ever hookah smokers
por: Sajid, Khan Mohammad, et al.
Publicado: (2008)

Colorectal Hyperplasia and Dysplasia Due to Human Carcinoembryonic Antigen (CEA) Family Member Expression in Transgenic Mice
por: Chan, Carlos H. F., et al.
Publicado: (2007)

Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis
por: Zou, Bin, et al.
Publicado: (2018)

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
por: Pao, William, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_6no6ea89dgvem5dtklocmlpp25